Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology - United Kingdom
doi 10.1002/hon.2437_3
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
Wiley